Stifel Financial Corp Reduces Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Stifel Financial Corp reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 48.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,659 shares of the company’s stock after selling 20,258 shares during the period. Stifel Financial Corp’s holdings in Moderna were worth $901,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. abrdn plc raised its holdings in shares of Moderna by 28.1% in the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after purchasing an additional 69,360 shares in the last quarter. Spire Wealth Management grew its position in shares of Moderna by 2,150.4% in the 4th quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock worth $966,000 after buying an additional 22,192 shares during the last quarter. Proficio Capital Partners LLC raised its stake in shares of Moderna by 4,418.9% during the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company’s stock worth $6,127,000 after acquiring an additional 144,099 shares in the last quarter. South Dakota Investment Council lifted its position in Moderna by 4.0% during the fourth quarter. South Dakota Investment Council now owns 299,399 shares of the company’s stock valued at $12,449,000 after acquiring an additional 11,500 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Moderna by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company’s stock valued at $300,219,000 after acquiring an additional 171,774 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the topic of several recent analyst reports. The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and reduced their target price for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. JPMorgan Chase & Co. decreased their target price on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Friday, March 21st. Leerink Partners lowered their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. William Blair restated a “market perform” rating on shares of Moderna in a research report on Thursday, April 17th. Finally, Bank of America cut their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $53.95.

Moderna Price Performance

Moderna stock opened at $24.25 on Friday. The stock has a market cap of $9.38 billion, a price-to-earnings ratio of -2.61 and a beta of 1.99. The firm has a 50 day simple moving average of $28.89 and a 200-day simple moving average of $36.57. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The company had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. During the same quarter last year, the firm posted ($3.07) earnings per share. Moderna’s revenue was down 35.3% compared to the same quarter last year. Equities analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.